Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Polycystic Ovary Syndrome 1Lymphoma, Follicular 1Diabetes Mellitus, Type 2 1Dementia 1Cognitive Dysfunction 1

Interventions

Pioglitazone 4Sitagliptin Phosphate 3Resistance Training 3Vildagliptin 2Sulfonylurea Compounds 2Nutritional Status 2Metformin 2Dipeptidyl-Peptidase IV Inhibitors 2Blood Specimen Collection 2voglibose 1saxagliptin 1repaglinide 1miglitol 1metahexamide 1meglitinide 1mazdutide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1alogliptin 1Urine Specimen Collection 1Troglitazone 1Tolbutamide 1Tolazamide 1Thiazolidinediones 1Surveys and Questionnaires 1Sodium-Glucose Transporter 2 Inhibitors 1Rosiglitazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Diabetes Mellitus, Type 2 × mazdutide × Clear all
NCT07083154 2026-03-05

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 3 Recruiting
420 enrolled
Lymphoid

Dementia, Diabetes Mellitus, Type 2, Lymphoma, Follicular, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡